Abstract | Chloride channels represent a relatively under-explored target class for drug discovery as elucidation of their identity and physiological roles has lagged behind that of many other drug targets. Chloride channels are involved in a wide range of biological functions, including epithelial fluid secretion, cell-volume regulation, neuroexcitation, smooth-muscle contraction and acidification of intracellular organelles. Mutations in several chloride channels cause human diseases, including cystic fibrosis, macular degeneration, myotonia, kidney stones, renal salt wasting and hyperekplexia. Chloride-channel modulators have potential applications in the treatment of some of these disorders, as well as in secretory diarrhoeas, polycystic kidney disease, osteoporosis and hypertension. Modulators of GABA A (γaminobutyric acid A) receptor chloride channels are in clinical use and several small-molecule chloride-channel modulators are in preclinical development and clinical trials. Here, we discuss the broad opportunities that remain in chloride-channelbased drug discovery.
Although there has been much activity in drug develop ment for cation (sodium, potassium and calcium) channel targets, considerably less attention has been given to chloride channels. This is partly because their identi fication and analysis has lagged behind those of other targets, and because of technical challenges in screening for chloridechannel modulators. Electrophysiologists have historically considered anion channel currents as 'unimportant leaks' associated with cation channels in excitable cells. Also, although there are toxins known to modulate sodium, potassium and calcium channels with high affinity and selectivity 1,2 -thereby allowing their functional and molecular characterization -comparable ligands for anion channels have yet to be identified.
Chloride channels are involved in a diverse set of functions in normal physiology and acquired diseases. Additionally, there are genetic diseases caused by muta tions in chloride channels (channelopathies) -the most common being cystic fibrosis, which has a prevalence of 1 in 2,000 Caucasians. Cystic fibrosis remains an incur able disease despite considerable knowledge of its genetic basis; there is a great need to develop drugs to restore normal chloridechannel function in cystic fibrosis cells.
Chloride transport across the cell plasma membrane is involved in key cellular events including cellvolume regulation, transepithelial fluid transport, muscle con traction and neuroexcitation. Within cells, chloride transport across organellar membranes is involved in endosomal, lysosomal and Golgi acidification. Chloride channels provide the major route for transmembrane chloride transport in these processes. In contrast to cation channels, which often show high selectivity for a specific ion, chloride channels are also permeable to other anions including other halides, the pseudohalide SCN -and bicarbonate. Mammalian chloride channels broadly fall into five classes based on their regulation: cystic fibrosis trans membrane conductance regulator (CFTR), which is activated by cyclic AMPdependent phosphorylation; calciumactivated chloride channels (CaCCs); voltage gated chloride channels (ClCs); ligandgated chloride channels (GABA (γaminobutyric acid) and glycine activated); and volumeregulated chloride channels (FIG. 1) . TABLE 1 summarizes these chloridechannel classes, their subtypes, molecular identities, functional properties, physiological roles, associated diseases and pharmaco logical modulators. Modulators of ligandgated chloride channels, such as barbiturates and benzodiazepines for GABA A gated chloride channels, are in clinical use. In addition, several compounds are in Phase II clinical trials for cystic fibrosis, including potentiators of mutant CFTRs and activators of CaCCs, which act by elevating cytoplas mic calcium. Candidate inhibitors of CFTR, CaCCs and ClCs have also been identified and are in various stages of preclinical development. Several attractive chloride channel targets remain relatively unexplored. This Review considers methods to assay chloridechannel function, with a focus on screening applications, and discusses the opportunities emerging from basic research for drug development for each of the chloridechannel classes. Assaying chloride-channel function Functional assay of chloridechannel activity is required for screening of chloridechannel modulators and for elucidation of their mechanism of action. until a few years ago, identification of chloridechannel modula tors was hampered by the lack of suitable probes for highthroughput assays. BOX 1 summarizes the princi ples of electrophysiological, concentrationbased and fluorescence methods that are now available to measure chloride transport, and their suitability for screening applications.
of particular utility are fluorescentproteinbased screening methods that use halidesensing green fluores cent protein (GFP) mutants. As a genetically encoded, intrinsically fluorescent protein of ~30 kDa, GFP can be targeted to the cell cytoplasm or to specific intracell ular sites. GFP fluorescence is sensitive to pH but not to halides. In the experiments depicted in FIG. 2Aa, halide sensitivity was conferred using a rational mutagenesis strategy based upon crystallographic data 3 , allowing halide penetration near the internal GFP chromophore. The emission maximum of the resultant yellow fluores cent protein (yFP) is redshifted by ~20 nm (to 528 nm) compared with GFP, and is reduced by increasing halide concentration. The fluorescence of the original halide sensing yFP, yFPH148Q, is 50% quenched by 100 mM chloride or 21 mM iodide 4 . yFPH148Q/I152l, discovered by mutation screen ing 5 , is highly sensitive to iodide compared with chloride (FIG. 2Ab) . The halidesensing mechanism of yFPs involves increases in their pK a with halide concentration: the pK a of yFPH148Q/I152l is 6.95 in the absence of chloride, increasing to 7.89 in 150 mM chloride (FIG. 2Ac) . yFPH148Q/I152l fluorescence responds over tens of milliseconds to changes in chloride concentration (FIG. 2Ab, inset) . yFPs can be stably expressed in cells where they are brightly fluorescent and strongly halide sensitive, although their fluorescence is sensitive to both halide concentration and to pH.
FIGURE 2B,C show two examples of yFP/cellbased screening assays for chloridechannel modulators. Screening for smallmolecule CFTR inhibitors 6 (FIG. 2B) required selection of cell lines that stably expressed a yFP halide sensor together with wildtype human CFTR. Key requirements of cell lines for CFTR screen ing include rapid growth on relatively inexpensive media, good adherence to plastic multiwell plates dur ing solution washing/exchange, low CFTRindependent halide permeability, and strong and stable expression of CFTR and the yFP sensor. In addition, an epithelial cell type is desirable because CFTR is normally expressed in these cells, and because they can form electrically tight monolayers that allow efficient secondary analysis of hits by measurement of shortcircuit current. FIGURE 2Ba illustrates primary screening in a 96well format with yFP/CFTRtransfected Fischer rat thyroid cells 7 . CFTR halide conductance is activated by an agonist mixture that targets different CFTR activation pathways, includ ing CFTR itself; the reasoning behind this approach is that active compounds identified in the screen would be expected to target CFTR itself. Following incubation with test compounds, fluorescence is measured briefly before, and for 12 seconds after addition of iodide to the extracellular solution. Iodide rather than chloride is used because of strong yFP quenching by iodide, and because CFTR, like most chloride channels, is permeable to iodide. Fluorescence following iodide addition is stable in the absence of agonists, but declines rapidly with agonists, with hits identified from their reduced nega tive slope (FIG. 2Bb) . As discussed below, several classes of smallmolecule CFTR inhibitors have emerged from this screen. 2 ) and a regulatory R domain. CFTR activation involves cyclic AMP-dependent phosphorylation and binding of ATP molecules at the NBDs. b | The overall organization of voltage-gated chloride (ClC) channels is depicted, showing 18 segments (labelled A to R) most of which span the plasma membrane partially and in a strongly tilted configuration. Fast gating involves flipping of a pore-lining glutamate side chain into and out of the chloride pathway. Channels are arranged as dimers with a slow gate controlling the activity of both channels simultaneously. c | The calcium-activated chloride channel (CaCC) TMEM16A (anoctamin-1), with predicted topology showing eight transmembrane segments with cytosolic amino and carboxy termini. The mechanism of calcium activation is unknown. d | GABA (γaminobutyric acid) and glycine-gated chloride channels, showing pentameric channels formed by α, β and γ subunits. Each subunit has four transmembrane segments, with a large extracellular N terminus. The second transmembrane segment of each subunit contributes to the formation of the central pore. The N termini of the α and β subunits form the ligand binding site. Volume-sensitive chloride channels (not shown) have an unknown molecular structure. They activate upon cell swelling. CBS, cystathione β-synthaserelated domain.
Meconium ileus
Often one of the early symptoms of cystic fibrosis consisting of intestinal obstruction by thickened meconium (fetal stool). FIGURE 2Ca illustrates a similar strategy used to identify smallmolecule inhibitors of a human intestinal CaCC. Because the molecular identity of this channel was not known at the time of the screening, phenotypebased screening was performed on a human intestinal epi thelial cell line (HT29) following stable expression of yFPH148Q/I152l using lentivirus 8 . The primary screen was done using a mixture of calciumelevating agonists, with the reasoning that the target of active compounds should be downstream of calcium signalling. As for the CFTR screen, the readout was yFP fluorescence quenching by iodide influx.
Targeting CFTR CFTR is a cAMPactivated chloride channel in the apical plasma membrane of epithelial cells in the airways, intestine, pancreas, sweat ducts, testis and other fluid transporting tissues 9, 10 . It is a member of the ATPbinding cassette (ABC) transporter superfamily. CFTR activa tion involves phosphorylation of multiple regulatory Rdomain sites and ATP binding and hydrolysis at its nucleotide binding domains 11, 12 .
The CFTR gene was identified in 1989 as the genetic basis of cystic fibrosis, which is an autosomal recessive disease 13 . The clinical features of cystic fibrosis include chronic lung infection with progressive deterioration of lung function, pancreatic exocrine insufficiency, male infertility, meconium ileus and various less common gastro intestinal complications 14 . lung disease is the principal cause of morbidity and mortality in cystic fibrosis, with current median life expectancy of 37 years in the united States (see the Cystic Fibrosis Foundation Patient Registry Annual Data Report 2006). More than 1,500 lossoffunction mutations in CFTR have been identi fied that cause cystic fibrosis, with approximately 90% of patients with cystic fibrosis having the ∆F508 muta tion (deletion of phenylalanine at 508 position) in one or both CFTR gene alleles. Although no gainoffunction CFTR mutations have been identified, inappropriately sustained activation of normal CFTR in intestinal epi thelial cells caused by enterotoxins produces secretory diarrhoea 15, 16 . CFTR activity in epithelial cells lining renal cysts is responsible for progressive fluid accumu lation and cyst enlargement seen in autosomal dominant Access of the patch pipette to the cell interior allows measurement of whole-cell macroscopic currents. The resultant macroscopic current-voltage relationship describes channel activity as a function of membrane potential. Voltage-dependence of membrane currents may be linear (ohmic response), inwardly-rectifying (larger currents at interior-negative potentials) or outwardly-rectifying (larger currents at exterior-negative potentials). For channels contained or expressed in epithelial cell monolayers having high electrical resistance, measurement of short-circuit current can provide quantitative information on channel activity and/or expression. As shown in panel Ab, short-circuit current is the transepithelial current applied to maintain zero transepithelial potential difference. Although short-circuit current depends in general on the activities of multiple transporters and on electrochemical driving forces, suitable experimental design can allow channel discrimination. While patch-clamp and short-circuit current measurements are of considerable use in secondary analysis of putative chloride-channel modulators, they are technically tedious for primary screening applications, even when using currently marketed high-throughput patch-clamp instruments. Electrophysiological measurements may be necessary to measure activity of certain ion channels, such as transiently gated sodium and potassium channels in excitable cells, but the relatively stable activation of most chloride channels allows the use of technically simple and relatively inexpensive methods for primary screening. Even for ligand-activated chloride channels, which show a transient response to GABA (γaminobutyric acid) and glycine, it is possible to apply screening methods based on anion flux.
Panel B shows concentration-based methods to assay chloride transport, which rely on changes in intracellular or extracellular chloride concentration in response to imposed chloride gradients. Concentration is measured using radioactive chloride ( Fluorescence methods are best suited for high-throughput identification of chloride-channel modulators. Chemical-type chloride-sensitive fluorescent indicators of the quinolinium class and iodide-sensitive fluorescent indicators of the luminarine class can be loaded into cells to provide a direct readout of cytoplasmic halide concentration 181, 182 . The fluorescence of these indicators is quenched by halides through a collisional mechanism.
Panel ca shows an assay in which indicator fluorescence is measured continuously following extracellular halide addition. 183, 184 . However, a limitation of membrane-potential-sensing methods to assay chloride channels is that cell membrane potential is determined by multiple factors, including cytoplasmic ionic composition and the activities of all ion channels; this can result in high false-positive rates.
Inwardly rectifying
The intrinsic ability of an ion channel to allow higher ion flux at negative (inwardly rectifying) or positive (outwardly rectifying) membrane potentials, even in the presence of a symmetrical concentration of the permeant ion.
Glycocalyx
The network of polysaccharides present on the surface of many cell types.
Intestinal loop model
A surgical technique to study fluid absorption/secretion in an isolated intestinal loop of a laboratory animal.
polycystic kidney disease (PKD) 17, 18 . As discussed below, therapies aimed at restoring function to mutant CFTRs would be of benefit in cystic fibrosis, whereas inhibiting CFTR function is desirable in enterotoxinmediated secretory diarrhoeas and PKD.
CFTR inhibitors.
Before the development of small molecule screening techniques, available inhibitors of CFTR chloride conductance included glibenclamide, diphenylamine2carboxylate, 5nitro2(3phenylpropyl amino)benzoate and niflumic acid, which are nonspecific in their action and of low potency 19 . Highthroughput screening of diverse smallmolecule collections (FIG. 2) has yielded two classes of CFTR inhibitors.
The first class includes the thiazolidinone CFTR inh 172 (FIG. 3Aa) , which acts on the cytoplasmic side of the plasma membrane to block CFTR chloride conductance with an IC 50 value of ~300 nM 6 . Patchclamp analysis indicated a voltageindependent channel blocking mechanism with prolongation of mean channel closed time 20 . This involves an interaction with arginine 347, which is located at the intracellular end of the CFTR pore 21 . CFTR inh 172 has low toxicity, undergoes renal excretion with minimal metabolism and accumulates in the intestine by entero hepatic recirculation 22 . It has been used extensively to block CFTR chloridechannel function in various cell culture, tissue and in vivo systems. Recent structureactivity studies have identified thiazolidinone CFTR inhibitors that are more water soluble than CFTR inh 172, including an analogue that substitutes the 4carboxyphenyl in CFTR inh 172 with 4tetrazolophenyl 23 . The second class of chemical CFTR inhibitors identified from screening was the glycine hydrazides (GlyH101 , FIG. 3Aa ). Patchclamp analysis showed that the CFTR current-voltage relationship changed from linear to inwardly rectifying in the presence of sub maximal concentrations of GlyH101 (REF. 24 ). Single channel CFTR currents showed rapid channel 'flicker' (opening and closing) following GlyH101 application, which, together with evidence that GlyH101 inhibition potency is dependent on the extracellular chloride con centration, indicates that GlyH101 acts by occluding the CFTR pore from its extracellular side. The exter nal site of action of the glycine hydrazides provided a unique opportunity to develop nonabsorbable com pounds for antidiarrhoeal therapy. Based on structureactivity studies showing that substitutions on the glycyl methylene group of the glycine hydrazide scaffold could be tolerated, nonabsorbable polyethylene glycol conjugates containing a malonic acid hydrazide (MalH) CFTRinhibiting moiety were synthesized and were found to fully inhibit CFTR when added at the external surface of cells 25 . various other MalH-macromolecular conjugates have been synthesized (generic structure shown in FIG. 3Ab ) with the goal of improving CFTR inhibition potency and resisting possible dilutional washout during severe diarrhoea. Conjugates of MalH with various lectins inhibited CFTR at doses in the nanomolar range and resisted washout for many hours, probably because of entrapment in the dense enterocyte glycocalyx 26 . Divalent MalH-polyethylene glycol conjugates, which inhibit CFTR by an apparent cooperative mechanism, also showed potency in the nanomolar range 27 . FIGURE 3Ba shows the mechanism of cholerainduced secretory diarrhoea. Cholera toxin from Vibrio cholerae increases cAMP levels, thereby activating CFTR. Consequent chloride secretion into the intestinal lumen drives sodium and water secretion. various rodent mod els of intestinal fluid secretion, including the closed intestinal loop model, open intestinal loop model and suckling mouse survival model, have confirmed anti diarrhoeal efficacy of the thiazolidinone and glycine hydrazide CFTR inhibitors. For example, FIG. 3Bb shows that a single intraperitoneal dose of CFTR inh 172 blocks choleratoxininduced fluid accumulation in closed ileal loops 28 . FIGURE 3Bc shows that oral administration of a MalH-lectin conjugate improves survival in suckling mice following oral administration of cholera toxin 26 . Smallmolecule CFTR inhibitors also reduce cyst expansion in models of PKD. Human autosomal domi nant PKD, which results from mutations in the interacting PKD1 and PKD2 genes, is a major cause of chronic renal insufficiency 29 . Cyst growth in PKD is characterized by epithelial cell hyperplasia coupled with CFTRdependent fluid secretion into the cyst lumen 30 (FIG. 3Ca) . In a proof ofconcept study, thiazolidinone and glycine hydrazide CFTR inhibitors slowed cyst expansion in both in vitro and in vivo models of PKD. Screening of CFTR inhibi tor analogues in an MDCK (epithelial) cell cyst model indicated near complete suppression of cyst growth by CFTR inh 172 and by an absorbable, phenylderivatized glycine hydrazide 31 . These compounds also reduced cyst number and growth by more than 80% in an embryonic kidney cyst model involving 4day organ culture of embryonic mouse kidneys in the presence of a cAMP agonist (FIG. 3Cb) . Subcutaneous delivery of the CFTR inhibitors to neonatal, kidneyspecific Pkd1 knockout mice, which normally develop large renal cysts in their first week of life, slowed their kidney enlargement and cyst expansion, and preserved renal function. Whether CFTR inhibition will be efficacious in human PKD, which has a much slower time course than that in PKD mouse models, will require clinical trials.
CFTR activators, potentiators and correctors.
Inhibitors of wildtype CFTR are predicted to reduce excessive intestinal fluid secretion in infectious diarrhoeas in which CFTR is inappropriately activated by bacterial enterotoxins. By contrast, activators of wildtype CFTR are predicted to increase basal intestinal fluid secretion and are therefore of potential utility in the treatment of constipation. Another potential therapeutic indication of wildtype CFTR activators is keratoconjunctivitis sicca (dry eye), a common disorder in the elderly in which the tear film is defective because of reduced lacrimal gland fluid secretion and/or excessive tearfluid evaporation. CFTR is strongly expressed in ocular surface epithelia where it functions, as in the intestine, in ion and fluid secretion 32 . CFTR can be activated by agents that elevate cAMP (such as receptor/G protein/adenylyl cyclase activators or phosphodiesterase inhibitors), stabilize Nature Reviews | Drug Discovery 
Airway surface liquid
The layer of fluid (thickness 7-10 μm) covering the airways that allows efficient beating of cilia for mucociliary clearance.
phosphorylated CFTR (phosphatase inhibitors) or act directly on CFTR (for example, flavones). A screening study identified nanomolarpotency smallmolecule CFTR activators with novel chemical structures that seemed to target CFTR directly 33 . Flavone analogues have also been synthesized with greatly increased CFTR activating potency compared with genistein 34 , a natural compound found in tofu that has multiple biological activities including CFTR activation. With a more direct mode of action, one would expect fewer offtarget effects of selective CFTRinteracting activators than of general modulators of cellular cAMP signalling.
Current cystic fibrosis therapies treat the symptoms rather than address the underlying CFTR defect, and include antibiotics, mucolytics (such as DNase), anti inflammatory agents, nebulized hypertonic saline and lung transplantation. Compounds that restore apical membrane chloride permeability in epithelia lacking normal CFTR function hold considerable promise. The most common CFTR mutation that causes cystic fibro sis, ∆F508, produces relatively chlorideimpermeable epithelial cells because of defective cellular processing of the channel protein, causing retention at the endo plasmic reticulum (ER), accelerated degradation and impaired chloridechannel gating [35] [36] [37] [38] (FIG. 4Aa) . Some less common mutations, which individually occur in less than 5% of patients with cystic fibrosis, include mutations that cause defective channel gating, such as G551D 39 , and premature CFTR truncation, such as W1282X 40 . of note, approximately onethird of all patients with cystic fibrosis harbour alleles other than ∆F508 (REF. 40 ), so therapies that are effective for these other mutations -such as gating or premature truncation mutations -might benefit more than 5% of the cystic fibrosis patient pop ulation. In developing chloridechannel enhancement therapy for cystic fibrosis, it is assumed that restoring chloride permeability would correct the underlying cellular defect that causes lung disease. However, the crucial link between CFTR dysfunction in cystic fibro sis and cystic fibrosis lung disease remains unresolved. As depicted in FIG. 4Ab , one theory suggests that the defect in the cystic fibrosis lung is reduced secretion of chloride, bicarbonate and fluid by airway submu cosal glands, resulting in a viscous, acidic airway surface liquid (ASl) that promotes bacterial colonization by impairment of mucociliary clearance and bacterial killing. Another theory proposes that the major defect in cystic fibrosis is epithelial sodium channel (ENaC) hyperactivity involving a CFTR-ENaC interaction, in which excessive sodium absorption by the airway surface produces ASl dehydration. If correct, ENaC inhibitors -which are under development -rather than CFTR activators, would be of greatest benefit. various other theories relating CFTR dysfunction to cystic fibrosis lung disease have been proposed, such as defective organellar function in airway epithelia, alveolar macrophage dysfunction, excessive ceramide accumulation and high ASl salt concentration [41] [42] [43] . As in other fields, the development and testing of therapies for cystic fibrosis are preceding full elucidation of disease pathogenesis.
Smallmolecule therapies are under development for cystic fibrosis caused by the ∆F508 mutation. Efforts have focused on two distinct types of compounds: cor rectors, which rescue defective ∆F508CFTR cellular processing and promote plasma membrane expression, and potentiators, which increase ∆F508CFTR open channel probability. A single compound with both types of activity is preferable.
Several classes of compounds act as potentiators, including flavones, xanthines, benzimidazoles and dihydropyridines 10, 19 . A general characteristic of poten tiators is that they are ineffective on wildtype CFTR when the channel is already maximally activated by cAMP, whereas they increase open probability of mutant CFTR even under conditions of maximal phosphoryla tion. Highthroughput screening efforts by two groups, each screening diverse collections of approximately 150,000 compounds, have identified additional small molecule potentiators [44] [45] [46] . Three classes of potentiators of nanomolar potency are shown in FIG. 4B. In addition to correcting defective gating of ∆F508CFTR, PG01 and compound vX770 (which has recently received orphan designation by the FDA) (FIG. 4Ba) correct the defective gating of other CFTR mutants, including G551DCFTR. vX770 is currently in Phase II clinical trials in patients with cystic fibrosis carrying the G551D mutation (see vertex web site). It remains unclear whether a poten tiator alone would benefit ∆F508 patients with cystic fibrosis because little, if any, ∆F508CFTR protein is expressed at the plasma membrane.
Identification of correctors that rescue ∆F508CFTR misprocessing presents a substantially greater challenge because of the complex, multistep nature of protein processing and the ubiquitous expression of genes encoding protein processing machinery. Some natural products and drugs, including curcumin 47 , miglustat (Zavesca; Actelion) 48 and sildenafil (Revatio/viagra; Pfizer) 49, 50 , while approved for other indications, have also shown ∆F508CFTR corrector activity. However, although curcumin has ∆F508CFTR potentiator func tion 51 , several laboratories could not confirm curcumin corrector activity [52] [53] [54] , thereby contradicting the original report. The compound 4phenylbutryate (Buphenyl; ucyclyd Pharma), a drug approved for an erythrocyte ureacycle disorder, increases ∆F508CFTR plasma membrane expression in cell culture models, possibly by nonspecific transcriptional enhancement and/or modu lation of interactions with the chaperone protein HSC70 (REF. 55 ). In Phase III clinical trials, a large dose (20 g three times a day) of 4phenylbutryate was tolerated, but produced only small increases in apparent ∆F508CFTR conductance in nasal potential difference measurements 56 . Several ∆F508CFTR correctors have been identified by highthroughput screening 46, 57, 58 ; structures of two examples are shown in FIG. 4Ca . Epithelial cells expressing ∆F508CFTR had increased shortcircuit currents when incubated with bisaminomethylbithiazole corr4a for 24 hours compared with the cells that had no compound exposure (FIG. 4Cb) . The restoration of the chloride cur rent is comparable to that conferred by lowtemperature rescue. Mechanismofaction studies suggest that
Polyspermia
Penetration of more than one spermatozoon into an oocyte at the time of fertilization.
Best vitelliform macular dystrophy
Early onset degeneration of the macula in retina causing loss of vision.
corr4a improves ∆F508CFTR folding, probably by a direct interaction, resulting in ERtoGolgi traffick ing and increased ∆F508CFTR stability 57 . Although the compounds shown in FIG. 4Ca correct the defective ∆F508CFTR processing in primary cultures of human airway epithelial cells from ∆F508 homozygous subjects, the chloride current after stimulation by forskolin and a potentiator is less than 20% of that in airway cell cultures from subjects who do not have cystic fibrosis. The per centage correction necessary to confer clinical benefit in cystic fibrosis remains unknown 59 , as does how findings in cell culture models translate to efficacy in patients with cystic fibrosis. Clinical trials are needed to establish efficacy of the various correctors under development.
'Readthrough' therapies aimed at bypassing prema ture termination codons caused by certain CFTR muta tions are under investigation. Gentamicin, which like other aminoglycosides has readthrough activity, was shown in human nasal potential difference measure ments to partially restore CFTR function 60 , but its renal and oto toxicity preclude longterm use in patients with cystic fibrosis. A more recent candidate, PTC124, which is under development for Duchenne muscular dystro phy, produces ribosomal readthrough of premature but not of normal stop codons 61 . Phase II clinical trials of PTC124 in cystic fibrosis caused by nonsense CFTR mutations show promise in nasal potential difference measurements 62 .
Targeting CaCCs
CaCCs are broadly expressed in mammalian cells where they are involved in a wide range of physiological func tions, including transepithelial fluid secretion, oocyte fertilization, olfactory and sensory signal transduction, smoothmuscle contraction, and neuronal and cardiac excitation. Wholecell current analysis indicates several common features between CaCC subfamilies, including slow activation following membrane depolarization, out wardly rectifying steadystate currents and greater iodide than chloride permeability. Singlechannel analysis has suggested four or more distinct CaCC subclasses, with a wide range of reported singlechannel conductances from less than 2 pS in cardiac myocytes to 50 pS in airway epithelial cells.
FIGURE 5a summarizes the cellular mechanisms in volved in the various physiological CaCC functions (reviewed in . CaCCs are activated in some cell types by direct action of calcium, as in salivary gland epithelium, or through calcium action on calcium/ calmodulin kinase II, as in intestinal epithelium. various stimuli cause elevation in cytoplasmic calcium, such as cholinergic agonists in glandular secretory epithelium, odorants in olfactory epithelium and pain in dorsal root ganglia neurons. These stimuli elevate cytoplasmic cal cium through the release of intracellular calcium stores via inositol 1,4,5trisphosphate (IP 3 ) signalling, and/ or calcium influx through plasma membrane voltage gated calcium channels. Increases in cytoplasmic cal cium can produce both membrane depolarization, by CaCC activation, and membrane hyperpolarization, by activation of calciumsensitive potassium channels.
The consequences of CaCC activation are celltype specific, for example, chloride secretion in epithelial cells, actionpotential generation in olfactory receptor neurons, smoothmuscle contraction, and prevention of polyspermia in oocytes. In some cell types, such as smooth muscle cells, membrane depolarization activates voltagegated calcium channels, increasing intracellular calcium concentration.
Although CaCCs were functionally characterized nearly three decades ago, their molecular identity has remained unclear until recently, with potential candi dates including bestrophins (BEST1-BEST4) 66, 67 , the calciumactivated chloride channel ClCA family pro teins 68 and ClC3 (REF. 69 ). It has been controversial whether these candidate gene products are chloride channels themselves, regulators of chloride channels or unrelated to chloride channels. The reader is referred to several recent reviews on this evolving subject 63, 70, 71 . of the various candidates, the bestrophins seemed to be the strongest contenders for bona fide CaCCs. Heterologous expression, mutagenesis and RNAi knockdown studies have provided evidence for their involvement in calciumactivated chloride currents 67, 72, 73 . Mutations in one of the four bestrophin subclasses, BEST1, which is expressed in retinal pigment epithelial cells, causes Best vitelliform macular dystrophy. However, recent evidence suggests that defective bestrophin causes pathology not through impaired chloride conductance, but by its role as a regulator of calcium channels 74 . Three independent laboratories have identified TMEM16A, also called anoctamin1, as a strong can didate for a CaCC [75] [76] [77] . Three different strategies were used: database searching for membrane proteins with multiple transmembrane segments and unknown func tion 75 , functional genomics following the observation that interleukin 4 (Il4)treated bronchial epithelial cells show increased CaCC activity 76 , and expression cloning using axolotl oocytes that do not have endog enous CaCC activity 77 . There is strong evidence to sug gest TMEM16A is a key component of CaCC, including similarity to native CaCCs in its electrophysiological properties, appearance of CaCC currents in various transfected cell systems, reduction in CaCC currents following RNAi knockdown, and its tissue distribution. TMEM16A has eight putative transmembrane segments (FIG. 1c) without domains evidently involved in calcium regulation.
A significant limitation in studying CaCCs has been the lack of potent or selective inhibitors. Available compounds -including fenamates, anthracene9car boxylic acid, indanyloxyacetic acid, ethacrynic acid and tamoxifen -have low potency, inhibit multiple types of chloride channels and transporters, and in some cases cause activation of large conductance calciumdependent potassium channels (BK Ca ) 9, 19, 63 . Recent smallmolecule screening to identify inhibitors of human intestinal CaCC(s), using the halideinflux assay described in 
Electrical organ
A specialized muscle-derived structure of fish belonging to the genus Torpedo that is able to produce electrical discharges of up to 220 volts.
Shunt conductance
A pathway that allows flow of ions (often chloride) in parallel with another pathway for ions of opposite charge. [78] [79] [80] , in reducing mucus secretion in asthma and cystic fibrosis 81 , and in the treatment of hypertension by reducing vascular resistance.
Osteopetrosis
By elevating cytoplasmic calcium, CaCC activators are thought to be of potential benefit in cystic fibrosis therapy as they might activate nonCFTR chloride channels in airway epithelial cells when CFTR is dys functional. This approach is based on the hypothesis that correction of reduced plasma membrane chloride per meability will be beneficial in cystic fibrosis, and in the case of CaCC activators, that activation of chloride chan nels by nonphysiological mechanisms will be beneficial. Two CaCC activator therapies are in clinical trials. The purinergic P2y2 receptor antagonist denufosol (INS37217) is in Phase II clinical trials, with a 28day treatment in patients with mild cystic fibrosis being well tolerated and showing preliminary evidence of potential benefit to lung function 82 . Moli1901 (duramycin) -a 19aminoacid residue bacterial polycylic peptide that elevates calcium by interaction with membrane phos pholipids -is also in Phase II clinical trials, with 5day inhalation therapy showing improvement in lung func tion 83 . The longterm efficacy of these therapies for cystic fibrosis requires further study. CaCC activators that target CaCCs directly without cytoplasmic calcium elevation have not been developed, but they might offer more tar geted therapy than general agonists of cellular calcium signalling. The recent identification of TMEM16A might facilitate the discovery of CaCCtargeted activators.
Targeting ClC-type chloride channels ClCs were discovered by expression cloning using mRNA isolated from the electrical organ of Torpedo marmorata, which has a very large chloride conductance generating high voltages 9, 84 . ClC family proteins are broadly expressed in prokaryotes and eukaryotes. In mammals, there are nine ClC genes that encode plasma membrane chloride channels (ClC1 (CLCN1), ClC2 (CLCN2), ClCKa (CLCNKA), and ClCKb (CLCNKB)) and intracellu lar proteins (ClC3 (CLCN3) The crystal structures of two bacterial ClC proteins have been determined 89 . The structures of eukaryotic ClCs, although not yet crystallized, have been modelled by homology to prokaryotic ClCs. In contrast to early models that were based on hydropathy analysis, ClC proteins have a complex topology with 18 segments, eight of which form hairpin structures that do not com pletely span the membrane (FIG. 1b) . The cytosolic car boxyl terminus of eukaryotic ClCs contains two copies of a cystathionineβsynthase motif that are important for protein-protein interactions and channel activity. one of the transmembrane segments contains a highly con served glutamate residue that is crucial for ClC channel and transporter functions 90 . For ClC channel function, movement of the glutamate carboxyl into and out of the pore seems to account for fast channel gating. For ClC transport function, the same carboxyl is involved in proton translocation across the membrane. It has been proposed that ClC channel function has evolved from its transporter function by loss of proton coupling 90 . Early electrophysiological analysis of chloride con ductance in the T. marmota electrical organ showed coordinated bursts of openings, suggesting the presence of a doublebarrelled channel containing two pores for chloride transport 91 . Similar results were obtained for cloned ClC0 (REF. 92 ) and ClC1 (REF. 93 ). Evidence from expression of heterodimeric channels suggests that the ClC channels (at least ClC0, ClC1 and ClC2) assemble as dimers, with each subunit forming a separate pore [92] [93] [94] . Analysis of ClC channel gating indicates a fast gate, occurring separately in each pore of the dimer, and a common gate that coordinates opening and closing of the two subunits at the same time. Whereas the fast gate involves the crucial glutamate residue mentioned above, the location of the common gate is less clear, but may involve cystathionineβsynthase domains at the dimer interface 95 . Naturally occurring mutations in ClC genes produce human diseases including myotonia, Dent's disease and osteopetrosis (TABLE 1) , and there is a con siderable body of phenotype data from mice lacking individual ClCs 9, 96 . ClC-1. ClC1 is a voltagedependent chloride channel with both fast and common gates opened by membrane depolarization. The fast gate in ClC1 (and ClC0) is strongly influenced by extracellular chloride con centration: a tenfold reduction in chloride shifts the current-voltage relationship by 40-60 mv to more posi tive (depolarizing) membrane potentials 97, 98 . ClC1 is expressed in skeletal muscle, where its expression in the sarcolemmal membrane is sensitive to innervation and muscle electrical activity 99 . ClC1 is responsible for the large chloride conductance in skeletal muscle allowing for membrane repolarization after each action potential. Action potentials that originate at the neuromuscular junction reach the interior of muscle fibre by travelling along the membrane of Ttubules, where depolariza tion triggers muscle contraction by calcium release from internal stores (FIG. 6a) . In other excitable cell types, termination of action potentials involves mem brane repolarization by potassium channels. However, in the small spaces of the Ttubule system, a potassium repolari zation current would increase extracellular potassium concentration and produce undesired mem brane depolarization and muscle contraction. ClC1 chloride conductance is an appropriate repolarizing Nature Reviews | Drug Discovery 
Endolymph
The potassium-rich fluid contained in the membranous labyrinth of the inner ear.
mechanism in muscle because extracellular chloride concentration is more than tenfold higher than that of potassium. As expected, lossoffunction mutations in ClC1 cause myotonia, which is characterized by exagger ated muscle contractions in response to normal stimuli. Depending on the mutation, myotonia congenita may be transmitted in a dominant (Thomsentype) or a recessive (Beckertype) pattern 100 . Mutations causing dominant myotonia typically affect the common gating mechanism, causing a shift in voltagedependence to more positive, nonphysiological membrane potentials. Recessive mutations may have various effects such as channel loss of function and altered voltage dependence 100 . ClC1 is also involved in dystrophic myotonia, where mutations occurring in a different gene, dystrophia myotonica protein kinase (DMPK), cause aberrant RNA splicing and ClC1 loss of function 101, 102 .
ClC-2.
ClC2 is a ubiquitously expressed, inwardly rectify ing chloride channel that is activated by cell swelling 103, 104 . ClC2 was thought to be involved in cellvolume regula tion, but it has different biophysical characteristics from the volumesensitive chloride channels that have been characterized in many tissues. It was anticipated that Clcn2 knockout mice would have an epileptic phenotype because ClC2 was predicted to maintain low cytoplasmic chloride in GABAergic neurons 105 . However, mice lacking ClC2 showed no evidence of epilepsy, and instead mani fested degeneration of photoreceptors in the retina and seminiferous tubules in the testicles 106 , which might be due to defective transepithelial ion transport in retinal pigment epithelium and Sertoli cells. Recent analysis of adult Clcn2 knockout mice revealed spongiform vacuola tion of white matter in the central nervous system, which might be related to defective oligodendrocyte function 107 . In humans, early data suggested an association between ClC2 mutations and idiopathic generalized epilepsy 108 . However, ClC2 mutations in subjects with epilepsy do not alter ClC2 function in vitro, and the same aminoacid changes are found in subjects without epilepsy 107, 109 .
ClC-Ka and ClC-Kb. ClCKa and ClCKb are renal chloride channels that are expressed in the thin and thick ascending limb of Henle's loop, respectively, where they provide a transcellular route for chloride reabsorp tion 9, 110 (FIG. 6b) . ClCKb is also highly expressed in other nephron segments including the distal convoluted tubule. Both renal ClCs show little voltage dependence owing to the presence of a valine instead of the gating glutamate found in other ClCs. lossoffunction muta tions in ClCKb cause Bartter's syndrome type 3, which is characterized by impaired NaCl reabsorption with hypokalaemia, hypochloraemia and alkalosis 111 . No diseasecausing ClCKa mutations have been reported. Mice lacking ClCK1 (the murine homologue of ClCKa) manifest nephrogenic diabetes insipidus with defective urinaryconcentrating ability 112 . A more severe renal saltwasting syndrome (Bartter's syndrome type 4) is caused by mutations in an unrelated protein, barttin, which is needed for correct plasma membrane expression of ClCKa and ClCKb 113 . This syndrome is therefore the functional equivalent of CLCNKA/ CLCNKB double knockout along the entire nephron, thereby explaining the greater severity of symptoms. In addition to renal disease, subjects with barttin muta tions manifest hearing impairment 114 , which is related to the involvement of ClCKa, ClCKb and barttin in marginal cells of the stria vascularis in the inner ear that secrete potassium into the endolymph. Potassium secre tion requires the coordinated action of the basolateral Na -cotransporter to pump potassium inside the cell; potassium is then secreted across the apical membrane through KCNQ1 channels, whereas chloride is recycled back across the basolateral membrane through ClCKa and ClCKb. The presence of both ClC channels in the same cells explains why subjects with only ClCKb mutations do not manifest hearing impairment. Interestingly, gainoffunction polymorphisms in ClCKa and ClCKb have been associated with hypertension. The common variant of ClCKb, T481S, shows greater chloride channel func tion than does wildtype ClCKb, and is associated with increased blood pressure 115, 116 . Single nucleotide poly morphisms in ClCKa are associated with salt sensitive hypertension 117 . These findings support the use of renal ClC inhibitors as novel antihypertensive agents, as previously proposed 111 .
Intracellular ClCs. Mutations in intracellular ClCs also cause human disease, by a common mechanism involving defective acidification of intracellular organelles. loss offunction mutations in ClC5 cause Dent's disease (FIG. 6c) , in which impaired receptormediated endo cytosis and endosomal acidification in renal proximal tubule cells result in proteinuria and kidney stones 118, 119 . Impairment of parathyroid hormone endocytosis by proximal tubule cells causes kidney stones by altera tion in calcium homeostasis and hyperphosphaturia 120 . ClC7 is expressed ubiquitously in late endosomes and lysosomes in many cell types. lossoffunction muta tions in ClC7 cause osteopetrosis 121 (TABLE 1) . ClC7 is transported by exocytosis to the ruffled border, an extension of the osteoclast plasma membrane that faces the resorption lacuna (FIG. 6d) , where it facilitates the secretion of HCl into the lacuna required for bone demineralization. As found for ClC5 and ClC4, ClC7 also functions as a 2Cl -/1H + antiporter 88 .
CIC inhibitors and potential drug targets.
There is a lack of selective, potent inhibitors of ClC proteins 9 . ClC1 is inhib ited at high micromolar concentrations by 9anthracene carboxylic acid (9AC) and by 2(pchlorophenoxy) propionic acid (CPP) analogues 122 . The differential inhibition of ClC0, ClC1 and ClC2 by 9AC, together with structural information from bacterial ClCs, sug gested the putative 9AC inhibitor binding site in ClC1 (REF. 123 ). ClC2 is inhibited by conventional chloride channel blockers such as 4,4′diisothiocyanostilbene 2,2′disulphonic acid (DIDS), 9AC and diphenylcar boxylate (DPC) at millimolar concentrations, but is more sensitive to 5nitro2(3phenylpropylamino) benzoic acid (NPPB) (90% inhibition at ~0.5 mM) 124 , Nature Reviews | Drug Discovery , although these metals are not selective in their action. The renal ClCs have been studied in more detail in terms of pharmacological modulators. Although ClCKa and ClCKb are highly homologous, ClCKa is more sensitive to DIDS and CPP 126 , which suggested the feasibility of developing selective blockers. Recently, phenyl benzofuran carboxylic acids were reported to block ClCKa and ClCKb with an IC 50 value of less than 10 μM 127 . It was also shown that fenamates like niflu mic acid act biphasically in the 0.1-1 mM range, with lower concentrations causing an approximately threefold increase in current, and higher concentrations causing inhibition 128 . Decrease of the dihedral angle between aromatic moieties switched activity from inhibition to activation, suggesting the possibility of developing ClC openers 127 . Wildtype ClC proteins represent potentially important drug targets. Inhibitors of renal ClCs might be useful as diuretic agents to treat hypertension and congestive heart failure. Selective action on ClCKa or ClCKb would avoid hearing impairment. ClC7 is a potentially important drug target. Pharmacological inhibition of ClC7 could reduce the activity of osteo clasts in osteoporosis, thereby preventing or reversing disease progression 129 . The chloridechannel inhibitor NS53736 was reported to inhibit bone resorption in a rat ovariectomy model of osteoporosis, resulting in increased bone density 130 , and inhibited osteoclast mediated pitting on bone slices in vitro. The authors proposed, without direct evidence, a mechanism involv ing ClC7 inhibition, although it was reported in the same study that NS53736 inhibited volumesensitive chloride channels.
little is known about the pharmacology of intracell ular ClCs, which, unlike plasmamembrane channels, cannot easily be studied at the functional level. For these proteins, novel screening methods are needed, perhaps based on measurement of Cl -/H + transport in intracell ular compartments. Alternatively, engineered protein sequences might allow their targeting to the plasma membrane and facilitate their functional assessment.
Most ClC mutations associated with genetic diseases cause loss of function and so are difficult drug targets. In principle, dominant mutations like those causing Thomsentype myotonia might be more amenable to At present, there is only one approved drug for which the target might be a ClC protein. lubiprostone (Amitiza; Sucampo Pharmaceuticals/Takeda) has been marketed for the treatment of chronic constipation. The rationale behind this indication is based on evidence that lubiprostone activates ClC2, which presumably causes an increase in intestinal fluid secretion as dis cussed above with regard to CFTR secretory mecha nisms. However, the evidence supporting lubiprostone action and ClC2 expression at the luminal membrane of enterocytes is weak 131 . There is conflicting evidence that ClC2 is expressed at a basolateral location 132, 133 , where ClC2 activation would be proabsorptive rather than prosecretory. In support of this conclusion is the finding that Clcn2 gene disruption in mice improves the survival of mice with cystic fibrosis 134 , the inverse of what would be expected were ClC2 prosecretory. The small benefit of lubiprostone in increasing the average frequency of bowel movements in clinical studies 135 might be related to a substantial subpopulation of sub jects with gastrointestinal side effects rather than to a prosecretory mechanism of action. Recent results sug gest that lubiprostone's effects could be due in part to activation of CFTR 136 .
Targeting ligand-gated chloride channels Inhibitory synaptic transmission involves ionotropic GABA and glycine receptors, which are of great impor tance in the brain and spinal cord, respectively. In GABA A , GABA C and glycine receptors, binding of the neurotrans mitter triggers the opening of a chloridepermeable pore [137] [138] [139] [140] . GABA B receptors are unrelated proteins, belonging to the superfamily of Gproteincoupled receptors. All GABA and glycineactivated chloride channels are pentameric proteins formed by the assem bly of different subunits (FIG. 1d) . For glycine receptors, there are four types of α subunit (α [1] [2] [3] [4] ) and one type of β subunit, with the usual stoichiometry being 2α 1 :3β 138 .
There are many more types of GABA subunits: α 1-6 , β 1-3 , γ 1-3 , δ, ε, π, θ and ρ 1-3 . Different combinations of these subunits generate GABA A and GABA C receptors. GABA A By contrast, GABA C receptors are homomers or hetero mers of ρ 1 , ρ 2 and ρ 3 subunits only. From the various sub unit types, a large number of GABA receptor isoforms can be generated. Although this large structural diversity presents a challenge to drug development, it represents a potentially unique opportunity for the development of selective modulators.
The subunits of ligandactivated chloride channels all share similar topology, with a large, extracellular aminoterminal domain (ECD) that contributes to the neurotransmitter binding site, four transmembrane domains and a short extracellular carboxyl terminus. The ECD contains a cysteine disulphide bridge sepa rated by 13 amino acids, a structure named the cysloop, which is also present in nicotinic acetylcholine recep tors and 5hydroxytryptamine 3 (5HT 3 ) receptors. The GABA or glycine binding site is formed at the interface between the ECDs of an α and a β subunit. The second transmembrane domain of each subunit is thought to constitute part of the channel pore involved in chlo ride translocation and gating 140, 141 . unlike the ClCs, in which each subunit forms a separate pore, a common pore in GABA and glycineactivated channels is formed at the centre of the pentamer by the assembly of the subunits 140, 141 . The inhibitory function of GABA and glycine recep tors is a consequence of the electrochemical potential for chloride. ligandgated chloride channels are excitatory in embryonic life and inhibitory in the developed nervous system 9, 142, 143 . In differentiated neurons, the activity of the K + /Cl -cotransporter (KCC2) lowers intracellular chlo ride concentration so that the equilibrium potential for chloride is more negative than the membrane potential (FIG. 7) . Accordingly, opening of GABA or glycine activated chloride channels in the postsynaptic membrane causes chloride influx and membrane hyperpolarization, suppressing excitability. In embryonic neurons, chlo ride concentration is higher because of reduced KCC2 expression, such that opening of ligandgated chloride channels causes membrane depolarization and opening of calcium channels 9, 142, 143 . Mutations in ligandgated chloride channels cause human genetic diseases. Startle disease (hyperekplexia) results from mutations in the α 1 subunit of the glycine receptor, and is characterized by an exaggerated reaction to unexpected acoustic or tactile stimuli that triggers attacks of muscle rigidity 144 . Mutations in GABA receptor subunits are associated with epilepsy [145] [146] [147] . GABA recep tor dysfunction has also been associated with depression and affective disorders 148 . Given their site of expression and role in the nervous system, GABA and glycine receptors are important pharmacological targets for natural toxic substances as well as for drugs with antiepileptic, anxiolytic, hypnotic and musclerelaxant activities [138] [139] [140] . GABA A receptors are targets of widely used sedative and hypnotic drugs including barbiturates and benzodiazepines, which interact with GABA A receptors at the interface of α and γ subunits and potentiate the GABA signal by an allo steric mechanism. The same site is targeted by inverse agonists such as βcarbolines, which have an effect opposite to that of anxiolytic benzodiazepines. Both agonists and inverse agonists are found in the same chemical class. Inverse agonists selective for the α 5 sub unit of the GABA A receptor, which is highly expressed in the hippocampus, were reported to enhance cognition in animals without anxiogenic and convulsant effects 149 . Such triazolophthalazines might therefore be useful in Alzheimer's disease and other dementias. Another example of a subunitspecific drug is gaboxadol, a selective agonist of GABA A receptors containing δ subunits, which are localized extrasynaptically in tha lamic neurons. Gaboxadol improved sleep duration and quality in Phase III clinical trials 150 , although its further development was discontinued.
GABA C receptors, composed only of ρ subunits, have a different pharmacological profile from GABA A receptors, with insensitivity to barbiturates and benzo diazepines, and selective sensitivity to the competitive antagonists (1,2,5,6tetrahydropyridine4yl) methyl phosphinic acid (TPMPA) and 4,5,6,7tetrahydroisoxaz ole [4,5c] pyridine3ol (THIP) 151 . The unique structural composition of GABA C receptors might be exploited to develop selective pharmacological modulators for visual, sleep and cognitive disorders 151, 152 . Despite their importance, glycineactivated chloride channels are not targets of existing drugs 140 . Glycine receptors, which are also activated physiologically by taurine and βalanine, are antagonized by the convulsant toxin strychnine. The importance of glycine receptors as drug targets has been demonstrated in animal models by showing their involvement in inflammatory pain sensi tization. The α 3 subunit of glycine receptors is inhib ited by prostaglandin E 2 dependent phosphorylation 153 . Consequently, mice lacking functional α 3 subunit show reduced pain perception. Glycine receptors are highly sen sitive to 5HT 3 receptor antagonists such as tropisetron 140 , which may suggest avenues for the development of more selective modulators.
GABA and glycine receptors are also involved in the action of substances of abuse including ethanol 154 and inhaled solvents 155 . The nalcohols bind to an aqueous cavity in the transmembrane segments, causing poten tiation of the inhibitory signal 156 . It has been proposed that this cavity undergoes volume changes during recep tor activation, with occupancy by nalcohols promot ing channel opening. Inhaled solvents such as toluene and trichloroethylene also enhance chloride currents through GABA A and glycine receptors with a similar site of action 155 .
Targeting volume-sensitive chloride channels volumesensitive chloride channels have been studied for about two decades using electrophysiological and radio isotope methods 157 . They are ubiquitous and typically activated by cell swelling in response to hypotonic shock. volumesensitive chloride channels generally show out ward rectification in their instantaneous current-voltage relationship, with larger currents produced immediately after changes in membrane potential to larger positive values. The currents show timedependent inactivation at positive membrane potentials and, of note, channel inactivation is accelerated at more positive membrane potentials 9, [158] [159] [160] . There is evidence that volumesensitive chloride channels are permeable to organic osmolytes such as taurine 161, 162 , but conflicting data suggest separate channels for chloride and taurine 163 .
Despite considerable effort, the molecular identity of volumesensitive chloride channels has yet to be established. various claims have been made and subse quently disproved. First, valverde et al. 164 reported that Pglycoprotein (also known as MDR1, ABCB1) over expression or silencing modulated volumesensitive chloridechannel activity. However, subsequent studies found no relationship between Pglycoprotein expression and chloridechannel activity 9 . A second candidate was the protein pICln identified by expression cloning [165] [166] [167] , but several groups could not confirm the membrane localization of pICln or its link with volumesensitive chloride channels [168] [169] [170] . It seems more likely that pICln is an intracellular protein with a role in spliceosome function 171 . Finally, ClC3 was proposed as a volume sensitive chloride channel, on the basis of outwardly rectifying volumesensitive chloride currents following overexpression and analysis of sitedirected mutants 172 . However, other investigators have challenged this claim. Mice deficient in ClC3 showed degeneration of cells in hippocampus and retina, without alteration of volume sensitive chloride currents 173 . Also, overexpression of ClC3 did not alter chloride currents of any type 174 . ClC3 is probably an intracellular chloride channel involved in endosomal acidification 173, 175 . one of the difficulties in studying volumesensitive chloride channels is the general lack of selective chan nel blockers or activators. volumesensitive chloride channels are inhibited at micromolar concentrations by the nonspecific compounds niflumic acid, NPPB, 1,9dideoxyforskolin and tamoxifen 9, 176 . A more selec tive inhibitor is 4(2butyl6,7dichlor2cyclopentyl indan1on5yl) oxybutyric acid (DCPIB) 177 , which blocks volumesensitive chloride channels at concentra tions that do not inhibit CFTR, ClC and CaCC. Selective, potent inhibitors would be of obvious utility in the iden tification of volumesensitive chloride channels and the study of their presumed physiological role in cellvolume regulation. Regulatory volume decrease in cells following exposure to a hypotonic solution involves the activation of potassium and chloride channels, resulting in net cell ular potassium chloride release and secondary osmotic water efflux. Release of taurine and other osmolytes through the same channels might also contribute to this process. It has been reported that volumesensitive chlo ride channels are involved in the cellvolume decrease underlying apoptosis 178 . using chloride channel blockers such as NPPB and phloretin, it was found that normo tonic cell shrinkage occurs early during apoptosis and that its pharmacological inhibition could prevent sub sequent cytochrome c release and caspase activation 179 . Selective inhibitors of volumesensitive chloride chan nels might therefore be useful in treating degenerative disorders involving apoptotic cell death. However, no specific ligands for these channels have been reported to date for in vivo applications.
Prospects for chloride-channel modulators
There is now an extensive body of information on chloridechannel function, biological roles and genetics. However, there remain notable gaps such as the lack of molecular identification of volumesensitive chloride channels. The recent identification of TMEM16A as a strong candidate for a CaCC [72] [73] [74] may reveal new physiological functions of CaCCs and CaCCrelated diseases. other members of the TMEM16A family, which number ten in mammals 180 , might also function as chloride channels. Because of the importance of CaCC activity in smooth muscle cells, TMEM16A inhibitors may be useful in treating hypertension and asthma. The overexpression of TMEM16A in various human tumours -which might be related to its involvement in proliferation, invasion and/or cellular homeostasis -suggests that TMEM16 inhibitors could be used in tumour therapy. Also of considerable promise are ClCsubtypeselective inhibitors as diuretics and for treatment of osteoporosis. Finally, GABAactivated ionotropic channels in the central nervous system, which are composed of multiple subunit combinations, represent potential targets for more selective agents in the treatment of anxiety, depression, epilepsy, insomnia and cognitive disorders.
Insights emerging from basic research indicate broad opportunities and challenges for chloridechannelbased therapies. Compounds under development offer promise for the treatment of cystic fibrosis, PKD and secretory diarrhoeas, for which the clinical trial outcomes are eagerly anticipated. The availability of efficient assays for primary screening of chloridechannel modulators offers drug discovery opportunities for many chloride channels, with the caveat that screening requires stable, plasmamembrane expression of functional channels. For example, screening for renal ClC modulators requires channel coexpression with its partner barttin, and screening of ligandactivated chloride channels requires cell lines stably expressing channels with precise subunit stoichiometry. ClC7 screening is particularly challeng ing because its intracellular location precludes the use of the conventional screening methods developed for plasma membrane chloride channels. Notwithstanding these technical challenges, there remain compelling and relatively unexplored opportunities in chloride channelbased drug discovery.
